Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8654847 | 0.95 | GRIN2D (0.35) | TSHRCYP19A1 | |
| SCHEMBL28827150 | 0.82 | SIRT2 (0.40) | CYP19A1 | |
| SCHEMBL8315536 | 0.81 | CYP19A1 (0.33) | TSHRCYP19A1 | |
| SCHEMBL21121157 | 0.81 | — | — | |
| SCHEMBL16283884 | 0.74 | GRIN2D (0.31) | — | |
| SCHEMBL4605079 | 0.72 | GRIN1 (0.38) | TSHR | |
| SCHEMBL28870848 | 0.72 | CYP19A1 (0.35) | MAPTCYP2C9TSHRCYP19A1CYP2C19 | |
| SCHEMBL15083625 | 0.68 | ALDH1A1 (0.33) | TSHR | |
| SCHEMBL4564982 | 0.67 | CYP19A1 (0.39) | CYP19A1 | |
| SCHEMBL29793069 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | CHENG KANG | 2011-05-19 | — | — | US | disclosed |
| EP-2295409-A1 | Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists | Merck Frosst Canada Limited (CA) | 2011-03-16 | — | — | EP | disclosed |
| EP-2286816-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | LDLR, HCAR1, FFAR1 | MAPT 4688/4885CYP2C9 2905/4885TSHR 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.